(RTTNews) - Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple myeloma have been accepted for regulatory review in ...
China’s National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted breakthrough therapy designation (BTD) for GSK's Blenrep (belantamab mafodotin ...
(Alliance News) - GSK PLC on Tuesday said its Blenrep cancer treatment will undergo review in Japan after successful authorisations recently in the UK and Europe. The London-based pharmaceutical ...
GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted for review a new drug application (NDA) for Blenrep (belantamab mafodotin) in combination with bortezomib plus ...
GSK continues to build the case for its multiple myeloma therapy Blenrep, which was pulled from the US market last year, with another positive phase 3 trial. The BCMA-targeted antibody-drug ...
GSK thinks its RSV vaccine can be a £3 billion product at its peak, and is also expecting a similar performance from Blenrep (belantamab mafodotin), recently approved for multiple myeloma ...
Japan's Ministry of Health, Labour and Welfare has also granted Blenrep orphan drug designation, which GSK said "reflects the high unmet medical need and ensures priority NDA review in multiple ...
The MHLW also granted orphan drug designation to Blenrep for multiple myeloma indication. Credit: CeltStudio/Shutterstock. Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted for review ...
(Alliance News) - GSK PLC on Tuesday said its Blenrep cancer treatment will undergo review in Japan after successful authorisations recently in the UK and Europe. The London-based pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback